Silo Pharma Collaborates With Kymanox to Develop Subcutaneous Ketamine Device for Potential Pain Relief

MT Newswires Live2024-11-29

Silo Pharma Inc (SILO) said Friday it has agreed to collaborate with Kymanox to design and develop a subcutaneous insertion device for SP-26, its ketamine-loaded implant for potential treatment of fibromyalgia and chronic pain.

Financial terms were not disclosed.

Under the agreement, Kymanox will come up with a proof-of-concept design followed by prototype and feasibility testing to determine the best insertion depth for the ketamine implants, the company said.

The company said it is conducting preclinical research into the safety of SP-26 with the aim of meeting US Food and Drug Administration requirements for at-home therapeutic designation.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2487554640?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-11-29 21:41","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2487554640","market":"sg","top_or_hot":-1,"title":"Silo Pharma Collaborates With Kymanox to Develop Subcutaneous Ketamine Device for Potential Pain Relief","media":"MT Newswires Live","content":"<html><body><p> Silo Pharma Inc (SILO) said Friday it has agreed to collaborate with Kymanox to design and develop a subcutaneous insertion device for SP-26, its ketamine-loaded implant for potential treatment of fibromyalgia and chronic pain.</p><p>Financial terms were not disclosed.</p><p>Under the agreement, Kymanox will come up with a proof-of-concept design followed by prototype and feasibility testing to determine the best insertion depth for the ketamine implants, the company said.</p><p>The company said it is conducting preclinical research into the safety of SP-26 with the aim of meeting US Food and Drug Administration requirements for at-home therapeutic designation.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Silo Pharma Collaborates With Kymanox to Develop Subcutaneous Ketamine Device for Potential Pain Relief</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSilo Pharma Collaborates With Kymanox to Develop Subcutaneous Ketamine Device for Potential Pain Relief\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-11-29 21:41 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.mtnewswires.com/><strong>MT Newswires Live</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Silo Pharma Inc (SILO) said Friday it has agreed to collaborate with Kymanox to design and develop a subcutaneous insertion device for SP-26, its ketamine-loaded implant for potential treatment of ...</p>\n\n<a href=\"https://www.mtnewswires.com/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"SILO","symbol_name":"SILO PHARMA INC.","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2487554640","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2487554640","pubTimestamp":1732887683,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Silo Pharma Inc  said Friday it has agreed to collaborate with Kymanox to design and develop a subcutaneous insertion device for SP-26, its ketamine-loaded implant for potential treatment of fibromyalgia and chronic pain.Financial terms were not disclosed.Under the agreement, Kymanox will come up with a proof-of-concept design followed by prototype and feasibility testing to determine the best insertion depth for the ketamine implants, the company said.The company said it is conducting preclinical research into the safety of SP-26 with the aim of meeting US Food and Drug Administration requirements for at-home therapeutic designation.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"SILO":"SILO PHARMA INC.","BK4202":"服装、服饰与奢侈品","BK4139":"生物科技"},"translate_title":"Silo Pharma与Kymanox合作开发皮下氯胺酮装置，用于潜在的疼痛缓解","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SILO":0.9},"content_text":"Silo Pharma Inc (SILO) said Friday it has agreed to collaborate with Kymanox to design and develop a subcutaneous insertion device for SP-26, its ketamine-loaded implant for potential treatment of fibromyalgia and chronic pain.Financial terms were not disclosed.Under the agreement, Kymanox will come up with a proof-of-concept design followed by prototype and feasibility testing to determine the best insertion depth for the ketamine implants, the company said.The company said it is conducting preclinical research into the safety of SP-26 with the aim of meeting US Food and Drug Administration requirements for at-home therapeutic designation.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.30.0","shortVersion":"4.30.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2487554640"}